Copper-Based Drug Shows Promise for Alzheimer’s Treatment

Researchers at Monash University have identified a copper-based drug, Cu(ATSM), that may present a novel approach to treating Alzheimer’s disease. In laboratory studies, the compound reduced harmful protein levels in the brain and enhanced memory. These findings are detailed in the journal ACS Chemical Neuroscience, indicating a potential therapy that focuses on the brain’s waste-removal system, a process often impaired in Alzheimer’s patients.

The Role of Toxic Proteins in Alzheimer’s

Alzheimer’s disease partly results from the accumulation of amyloid-beta proteins in the brain. Normally, these proteins are removed through the blood-brain barrier, a protective mechanism that regulates substances entering and exiting the brain. However, in patients with Alzheimer’s, this system’s efficiency declines, allowing toxic proteins to build up. P-glycoprotein (P-gp) pumps, which help transport waste from the brain to the bloodstream, play a vital role. When these pumps fail, the brain struggles to remove toxic substances.

Study Insights on Cu(ATSM)

The study suggests Cu(ATSM) can help restore this clearance system by enhancing the number and activity of P-gp pumps. Dr. Jae Pyun, the lead author, noted that the treatment improves brain blood vessel function, resulting in reduced toxic protein levels and better cognitive performance. “This is the first study to show that Cu(ATSM) can increase the abundance of P-gp clearance pumps in an Alzheimer’s model by 24.1 percent, effectively linking blood-brain barrier repair to a reduction in toxic proteins and improved cognitive function,” stated Dr. Pyun.

The research demonstrated measurable effects; over a 56-day period, the treatment lowered amyloid-beta levels by 42 percent and enhanced spatial learning by nearly 44 percent. These results suggest that fixing the blood-brain barrier might be key to addressing Alzheimer’s damage.

A Drug with Previous Testing

Professor Joseph Nicolazzo, a senior author, highlighted that Cu(ATSM) could progress to human trials more swiftly compared to other experimental therapies, as it has already been tested for safety in other neurological disorders. “Cu(ATSM) is a copper compound with anti-inflammatory and neuroprotective properties that has advanced to clinical testing for conditions like Parkinson’s and ALS,” Nicolazzo explained. He emphasized the importance of reducing amyloid levels for symptom improvement. “Because reducing amyloid burden is clinically proven to improve functional outcomes, these preclinical results strongly support the rationale for testing this drug in early symptomatic Alzheimer’s disease.”

Ongoing Questions

While the findings offer hope, further research is needed to understand how amyloid-beta exits the brain once the blood-brain barrier is restored. One theory suggests Cu(ATSM) may also enhance the activity of microglia, immune cells that help dismantle toxic proteins. Dr. Dayan Goodenowe, a neuroscientist not directly linked to the study, mentioned that targeting the blood-brain barrier and waste-clearance systems is promising, as Alzheimer’s involves more than plaque accumulation. He pointed out that Alzheimer’s encompasses various biological aspects, including membrane biology, inflammation, vascular function, lipid metabolism, and cellular resilience.

Goodenowe remarked, “The crucial inquiry is not merely if amyloid changes, but if the intervention enhances cognition, functioning, and outcomes in humans. The research must transition from mechanism and preclinical work to human safety, dosage, efficacy, and ultimately FDA validation.”

Implications for Future Treatments

Future studies will delve deeper into these pathways. Currently, the results underscore the potential of therapies targeting blood vessel function and protein clearance in the brain. As dementia rates escalate and effective treatment demand grows, the study provides early evidence that repairing the brain’s natural waste-clearance mechanism might be vital for upcoming Alzheimer’s therapies.